[go: up one dir, main page]

AU2003210266A8 - Treatment, diagnosis and imaging of disease - Google Patents

Treatment, diagnosis and imaging of disease

Info

Publication number
AU2003210266A8
AU2003210266A8 AU2003210266A AU2003210266A AU2003210266A8 AU 2003210266 A8 AU2003210266 A8 AU 2003210266A8 AU 2003210266 A AU2003210266 A AU 2003210266A AU 2003210266 A AU2003210266 A AU 2003210266A AU 2003210266 A8 AU2003210266 A8 AU 2003210266A8
Authority
AU
Australia
Prior art keywords
diagnosis
imaging
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003210266A
Other versions
AU2003210266A1 (en
Inventor
Mats Ehinger
Sara Ek
Carl Arne Krister Borrebaeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203480A external-priority patent/GB0203480D0/en
Priority claimed from GB0215095A external-priority patent/GB0215095D0/en
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Publication of AU2003210266A1 publication Critical patent/AU2003210266A1/en
Publication of AU2003210266A8 publication Critical patent/AU2003210266A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003210266A 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease Abandoned AU2003210266A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0203480A GB0203480D0 (en) 2002-02-14 2002-02-14 Treatment diagnosis and imaging of disease
GB0203480.9 2002-02-14
GB0215095A GB0215095D0 (en) 2002-06-29 2002-06-29 Treatment, diagnosis and imaging of imaging of disease
GB0215095.1 2002-06-29
PCT/EP2003/001461 WO2003068268A2 (en) 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease

Publications (2)

Publication Number Publication Date
AU2003210266A1 AU2003210266A1 (en) 2003-09-04
AU2003210266A8 true AU2003210266A8 (en) 2003-09-04

Family

ID=27736212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210266A Abandoned AU2003210266A1 (en) 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease

Country Status (2)

Country Link
AU (1) AU2003210266A1 (en)
WO (1) WO2003068268A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2002318364A1 (en) 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7482322B2 (en) * 2003-10-30 2009-01-27 Kazusa Dna Research Institute Foundation Plexin family-like polypeptide, and uses thereof
GB2435882A (en) * 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
KR101958753B1 (en) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human cd27 and uses thereof
PE20142242A1 (en) 2012-03-15 2015-01-08 Janssen Biotech Inc ANTI-CD27 HUMAN ANTIBODIES, METHODS, AND USES
MX2020010913A (en) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2002004021A1 (en) * 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CA2411102A1 (en) * 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination

Also Published As

Publication number Publication date
WO2003068268A3 (en) 2004-03-11
WO2003068268A2 (en) 2003-08-21
AU2003210266A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
EP1804661A4 (en) Integrated disease diagnosis and treatment system
HUP0401127A3 (en) Treatment and diagnosis of macrophage disease
AU2002303295B2 (en) Diagnosis and treatment of neural disease and injury using microvoltammetry
AU2003265831A8 (en) Hyperspectral imaging of the human retina
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
AU2003293460A1 (en) Novel application of biosensors for diagnosis and treatment of disease
EP1551990A4 (en) Diagnosis and treatment of chemoresistant tumors
IL162201A0 (en) New methods for diagnosis and treatment of tumours
PL1623228T3 (en) Apociii and the treatment and diagnosis of diabetes
IL163547A0 (en) Use of the axl receptor for diagnosis and treatment of renal disease
AU2003286726A8 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
GB0320238D0 (en) Treatment of disease
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
GB0218879D0 (en) Medical treatment
AU2003210266A8 (en) Treatment, diagnosis and imaging of disease
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
GB9909392D0 (en) Treatment, imaging and diagnosis of disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
EP1773882A4 (en) Diagnosis and treatment of siglec-6 associated diseases
GB0215095D0 (en) Treatment, diagnosis and imaging of imaging of disease
GB0317586D0 (en) Treatment, diagnosis and imaging of disease
AU2002319591A1 (en) Diagnosis and treatment of vascular disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase